Workflow Orchestration for Hematological Oncology

Data Characteristics

Hematological oncology pharmacovigilance data originates from clinical trial reports, real-world evidence (RWE), adverse event (AE) reports from physicians and patients, and safety updates from global regulatory bodies. This data often combines unstructured text (e.g., clinical notes, AE descriptions) and semi-structured data (e.g., MedDRA codes, drug names, dosages, patient characteristics).

Clinical trial data is typically released in batches after trial completion. Real-world data and AE reports update continuously and frequently, especially during new drug launches. Document structures vary, including PDF clinical study reports, HL7 CDA documents, and structured reports based on CIOMS I or MedWatch forms.

Fields include general patient demographics, drug information, and AE descriptions. Hematology-specific indicators are also present, such as complete blood count (CBC), bone marrow cytology results, flow cytometry data, and hematological malignancy progression assessments (e.g., RECIST criteria). Units involve common laboratory indicators (e.g., g/dL, cells/µL, %) and drug dosage units (mg, IU).

Constraints Imposed by These Characteristics on Workflow Orchestration

The heterogeneous nature of hematological oncology pharmacovigilance data requires multiple data ingestion modules in workflow orchestration. Frequent and continuous AE report updates demand real-time or near real-time processing capabilities to avoid delays in identifying critical signals.

The mixture of unstructured text and structured data necessitates integrating natural language processing (NLP) modules for information extraction and entity recognition within the workflow. Examples include identifying MDS (Myelodysplastic Syndromes) progression or AML (Acute Myeloid Leukemia) relapse signs from medical record texts.

The presence of hematology-specific indicators requires models to understand and associate these specialized terms. For instance, linking platelet count < 50,000/µL with bleeding risk. Additionally, drug interactions and polypharmacy are common in hematological oncology patients. Workflows need to support complex multi-condition judgments and branching logic to accurately assess the association between adverse events and specific drugs. Document format diversity also places demands on file parsing modules, requiring handling of various input formats.

Configuration Settings

Configuration Item	Recommended Value	Rationale
`maxContext`	`8000 tokens`	Hematological oncology adverse event reports often contain detailed medical history and laboratory data, requiring a longer context window for comprehensive understanding.
`Chunk size`	`500 characters`	Ensures text segmentation retains complete medical concepts and phrases, facilitating subsequent entity recognition and semantic analysis.
`Similarity threshold`	`0.75`	For precise matching of medical terms and adverse event descriptions, avoiding misjudgments due to semantic similarity but different medical meanings.
`Recall count`	`Top 10 entries`	Given the complexity of hematological malignancies, recalling more relevant knowledge aids in decision-making and improves relevance.
`PARSE_FILE_TIMEOUT_SECONDS`	`300 seconds`	Processing large PDF clinical trial reports or documents containing many images requires longer parsing times.
`Max Tool Call Attempts`	`3 times`	External tools (e.g., MedDRA encoders) may experience occasional network fluctuations or service overload, necessitating a retry mechanism.

Common Pitfalls

Symptom: The workflow fails to correctly identify key hematological indicators or disease progression in some adverse event reports. Reason: The model insufficiently understands specialized medical terminology, or the knowledge base lacks deep medical knowledge in relevant areas.
Symptom: token or global variables passed within the workflow appear empty or undefined in subsequent tool calls. Reason: Global variable lifecycle or scope configuration is incorrect, preventing downstream modules from properly acquiring them.
Symptom: The workflow experiences processing delays or timeouts when handling high-concurrency AE reports. Reason: Insufficient computational resources for file parsing modules or complex inference modules, failing to effectively handle sudden workloads.

Validation of Configuration

Select a batch of test data including various document formats (PDF, HL7 CDA, structured tables) and typical hematological oncology adverse events (e.g., myelosuppression, bleeding, infection). Run the workflow and verify the accuracy of key information extraction (e.g., drugs, dosages, adverse event types, MedDRA codes).
Monitor workflow logs for error messages such as global variable undefined or tool call failed. Verify that global variables are passed as expected between modules.
For representative complex cases, examine the workflow's decision path and inference results. Ensure consistency with expert medical judgment, especially regarding drug-adverse event association assessment.
Simulate high-concurrency data input scenarios. Observe the workflow's average processing time and resource utilization. Compare these against expected performance metrics to determine if throughput and stability meet requirements.

The values given are common starting points and should be measured against the reader's own samples.

Question material comes from public community discussions. Configuration values are common starting points and should be measured against your own samples. Verified on 2026-09-21.